Galderma Maintains 2025 Outlook Despite Tariff Uncertainty
ZURICH (Reuters) -Swiss skincare company Galderma on Thursday said its sales rose by 8.3% on the year to $1.13 billion during the first quarter and signalled confidence about its prospects for the rest of 2025 despite ongoing uncertainty over U.S. tariffs.
Chief Executive Officer Flemming Ornskov told Reuters the company was sticking its outlook for 2025 as it rolls out new products and pursues increased market share, stressing that Galderma was "totally committed to the U.S."
"The vast majority of our portfolio is not affected by these tariffs right now," Ornskov said, noting that only nine percent of the firm's total sales were impacted by import duties.
"The way we want to manage this situation is to focus on commercial execution, volume, market share gain," he added.
Galderma, which launched on the Swiss stock exchange in March 2024, saw its shares gaining 8.5% in early trading after the results.
Bank Vontobel analyst Stefan Schneider said Galderma's results were positive.
"Over-delivery of 1Q25 sales allows the company to increasingly de-risk and confirm its FY25 guidance despite some further tariff impact in some consumer product categories," he said.
(Writing by Dave Graham, editing by John Revill)